DIABETES Dapagliflozin-redefining treatment of T2DM?

被引：1
|
作者：
Chao, Edward C. [1 ,2 ]
机构：
[1] Univ Calif San Diego, Div Endocrinol & Metab, San Diego, CA 92161 USA
[2] VA San Diego, San Diego, CA 92161 USA
来源：
NATURE REVIEWS ENDOCRINOLOGY | 2011年 / 7卷 / 12期
关键词：
INADEQUATE GLYCEMIC CONTROL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; METFORMIN; THERAPY;
D O I：
10.1038/nrendo.2011.177
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently, glycosuria has been regarded only as a consequence of T2DM, but dapagliflozin employs glycosuria as a mechanism of treatment. Will this paradigm shift gain acceptance?
引用
收藏
页码：696 / 697
页数：3
相关论文
共 50 条
  • [1] Dapagliflozin—redefining treatment of T2DM?
    Edward C. Chao
    Nature Reviews Endocrinology, 2011, 7 : 696 - 697
  • [2] Safety of Dapagliflozin in Clinical Trials for T2DM
    Ptaszynska, Agata
    Johnsson, Kristina M.
    Apanovitch, Anne Marie
    Sugg, Jennifer E.
    Parikh, Shamik J.
    List, James F.
    DIABETES, 2012, 61 : A258 - A259
  • [3] Genital Infections in Asian Patients with T2DM Receiving Dapagliflozin Treatment
    Ji, Linong
    Nishimura, Rimei
    Cho, Young Min
    Sjostrom, David
    Johnsson, Kristina M.
    Johnsson, Eva
    DIABETES, 2015, 64 : A658 - A658
  • [4] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [5] Durability of Dapagliflozin Treatment Response in Patients With T2DM: 2-Year Results
    Salsali, Afshin
    Rohwedder, Katja
    Mansfield, Traci
    Martin, Paula
    Wei, Li
    Parikh, Shamik
    DIABETES, 2012, 61 : A264 - A264
  • [6] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [7] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [8] Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients
    Reactions Weekly, 2022, 1900 (1) : 6 - 6
  • [9] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) and Concomitant Heart Failure
    Kosiborod, Mikhail
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Sugg, Jennifer E.
    Johnsson, Eva
    DIABETES, 2015, 64 : A313 - A313
  • [10] Dapagliflozin Is Safe and Well Tolerated in Older Patients with T2DM
    Mansfield, Traci
    Fioretto, Paola
    Ptaszynska, Agata
    Yavin, Yshai
    Apanovitch, Anne Marie
    Johnsson, Eva
    Parikh, Shamik J.
    List, James F.
    DIABETES, 2014, 63 : A71 - A71
12345